Viatris (VTRS) Stock Forecast & Price Target

Viatris is well positioned because its core generics business appears to be stabilizing after several years of divestitures, manufacturing disruptions, and regional headwinds, with 1H26 developed-markets growth returning on the back of Breyna, estradiol, and new US launches. Its growth algorithm is becoming more durable as it targets roughly 70% of the $175 billion branded-drug patent cliff from 2025-2030 and shifts toward complex generics, which should support better margins and more resilient revenue. On top of that, the pipeline adds meaningful upside through fast-acting meloxicam, the estradiol and contraceptive patch franchise, and longer-dated catalysts such as selatogrel and cenerimod, while adjusted EBITDA is modeled at $4.6 billion in CY27.

Viatris is viewed cautiously because its core generics business remains exposed to pricing pressure and competitive intensity, even as the U.S. mix shifts toward more complex generics that may not fully offset headwinds. The downside case is amplified by pipeline concentration: selatogrel is a key contributor to a $1Bn-plus peak sales estimate, while cenerimod already faces skepticism after the Phase 2b CARE study missed its primary endpoint. In addition, APAC growth assumptions depend on regional CAGR targets, but Greater China faces volume-based procurement and JANZ is seeing structural generic price reductions, while Gwyn Lo may mainly cannibalize XULANE rather than expand the market.